Read Jennifer R, Boston Raymond C, Abraham Getu, Bauquier Sebastien H, Soma Lawrence R, Nolen-Walston Rose D
Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, USA.
Am J Vet Res. 2012 Jan;73(1):140-5. doi: 10.2460/ajvr.73.1.140.
To determine whether prolonged administration of clenbuterol results in tachyphylaxis, specifically regarding its bronchoprotective properties and effect on sweating in horses.
8 Thoroughbreds with inflammatory airway disease.
In a crossover design, horses received clenbuterol (0.8 μg/kg, p.o., q 12 h) or placebo for 21 days, with a washout period of ≥ 30 days between the 2 treatments. Airway reactivity was evaluated by use of flowmetric plethysmography and histamine broncho-provocation before (day 0; baseline) and every 7 days after the start of treatment. Sweat function was evaluated via response to epinephrine administered ID before and every 10 days after the start of treatment.
The concentration of histamine required to increase total airway obstruction by 35% (PC35) was significantly reduced during treatment with clenbuterol (mean change, 11.5 mg/mL), compared with during administration of the placebo (mean change, -1.56 mg/mL), with a peak effect at 14 days. Tachyphylaxis was evident by day 21, with 7 of 8 horses having a PC35 below the baseline value (mean change, -0.48 mg/mL), which returned to baseline values during the washout period. No effect of clenbuterol was seen in sweat response to epinephrine administration.
Clenbuterol initially reduced airway sensitivity to inhaled histamine, but tachyphylaxis that resulted in increased airway reactivity was evident by day 21. Although no effects on sweating were detected, the technique may not have been sensitive enough to identify subtle changes. Prolonged administration of clenbuterol likely results in a clinically important reduction in its bronchodilatory effects.
确定长期使用克伦特罗是否会导致快速耐受,特别是关于其对马匹的支气管保护特性和出汗的影响。
8匹患有炎性气道疾病的纯种马。
采用交叉设计,马匹接受克伦特罗(0.8μg/kg,口服,每12小时一次)或安慰剂治疗21天,两种治疗之间的洗脱期≥30天。在治疗前(第0天;基线)以及治疗开始后每7天,通过流量容积描记法和组胺支气管激发试验评估气道反应性。在治疗前以及治疗开始后每10天,通过对皮内注射肾上腺素的反应评估出汗功能。
与给予安慰剂期间(平均变化,-1.56mg/mL)相比,在用克伦特罗治疗期间,使总气道阻塞增加35%所需的组胺浓度(PC35)显著降低(平均变化,11.5mg/mL),在第14天达到峰值效应。到第21天快速耐受明显,8匹马中有7匹的PC35低于基线值(平均变化,-0.48mg/mL),在洗脱期恢复到基线值。在对肾上腺素给药的出汗反应中未观察到克伦特罗的作用。
克伦特罗最初降低了气道对吸入组胺的敏感性,但到第21天,导致气道反应性增加的快速耐受明显。尽管未检测到对出汗的影响,但该技术可能不够灵敏,无法识别细微变化。长期使用克伦特罗可能会导致其支气管扩张作用在临床上出现重要降低。